Preventing Type 1 Diabetes: The leadership role of JDRF

By Richard Insel, M.D. As JDRF remains steadfast in its mission of curing type 1 diabetes, we are also committed to both improving treatments for individuals with the disease and preventing the disorder itself. Our treatment priorities include developing new drugs and devices that significantly improve glucose control, reduce the daily burden of living with […]

New Findings about the Transformers: Alpha Cells

Alpha-to-beta cell conversion or “reprogramming” is an early, but promising, therapeutic strategy for T1D. Scientists have now shown that the body can function normally without most of its alpha cells, addressing a potential safety concern for alpha-to-beta cell conversion.

Retinopathy Basics Q&A: What You Need to Know

Q: What is diabetic retinopathy? A: Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. Diabetic retinopathy is a progressive disease that destroys small blood vessels in the retina, eventually causing vision problems. In its most advanced form–proliferative retinopathy–it can cause blindness. According to the National […]

Special Diabetes Program Renewed by Congress!

Congress passed the Special Diabetes Program (SDP) in December 2010, committing $150 million per year to extend the program for an additional two years. The legislation marks the fifth time since 1997 that Congress has supported SDP, underscoring the government’s commitment to accelerating the search for a cure and the development of new treatments for […]

Up Close: “Leaving My Comfort Zone”

By Kathryn Larson I still wonder, “What was I thinking?” I had spent my entire life in a secure community near Denver, yet when I was presented with the opportunity to take a two-week tour of Vietnam, I jumped at it – in spite of the fact that not only was I new to travel, […]

JDRF and Amylin to Test Hormone for Blood Glucose Control

JDRF and Amylin are enthusiastic about the potential of metreleptin to help improve blood glucose control in people with type 1 diabetes. A successful outcome in the metreleptin study would likely lead to studies with larger numbers of people and the development of alternative treatments to using medical insulin alone.